中西医结合治疗肝纤维化研究进展与思考*

doi:10.3969/j.issn.1672-5069.2025.06.002

Abstract

Li Sisi, Jiang Yanzhen, Fu Zhaoyuan. Chinese traditional and western medicine in the treatment of liver fibrosis:current state of the art, controversies, and perspectives[J]. Journal of Practical Hepatology, 2025, 28(6): 805-808.

References

[1] Parola M, Pinzani M. Liver fibrosis:pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med,2019,65:37-55.
[2] 中国中西医结合学会肝病专业委员会. 肝纤维化中西医结合诊疗指南(2019年版).中华肝脏病杂志,2019,27(7):494-504.
[3] Khanam A, Saleeb PG, Kottilil S. Pathophysiology and treatment options for hepatic fibrosis:can it be completely cured? Cells,2021,10(5):1097.
[4] Zhu Y, Chai Y, Xiao G, et al. Astragalus and its formulas as a therapeutic option for fibrotic diseases: pharmacology and mechanisms. Front Pharmacol,2022,13:1040350.
[5] Sun X, Zheng Y, Tian Y, et al. Astragalus polysaccharide alleviates alcoholic-induced hepatic fibrosis by inhibiting polymerase I and transcript release factor and the TLR4/JNK/NF-κB/MyD88 pathway. JEP,2023,314:116662.
[6] Yang Z, Qi J, Ping D, et al. Salvia miltiorrhiza in thorax and abdomainal organ fibrosis:a review of its pharmacology. Front Pharmacol,2022,13:999604.
[7] Ying Q, Teng Y, Zhang J, et al. Therapeuticeffect of tanshinone IIA on liver fibrosis and the possible mechanism: apreclinical meta-analysis. Evid Based Comple Alt,2019,2019:7514046.
[8] Li Q, Huang D, Liao W, et al. Tanshinone IIA regulates CCl₄ induced liver fibrosis in C57BL/6J mice via the PI3K/Akt and Nrf2/HO-1 signaling pathways. J Biochem MolToxic,2024,38(2):e23648.
[9] 施光峰,李谦,翁心华,等. 苦参素对大鼠纤维化肝脏金属蛋白酶-1和α-平滑肌肌动蛋白表达的影响.中华肝脏病杂志,2004,12(1):56-56.
[10] Song LY, Ma YT, Fang WJ, et al. Inhibitory effects of oxymatrine on hepatic stellate cells activation through TGF-β/miR-195/Smad signaling pathway. BMCComplem Altern Med,2019,19:1-9.
[11] Sun S, Zhang G, Lyu S, et al. Potential mechanisms of traditionalChinese medicine in the treatment of liver cirrhosis: a focus on gut microbiota. Front Microbiol,2024,15:1407991.
[12] He X, Liang J, Li X,et al. Dahuang zhechong pill ameliorates hepatic fibrosis by regulating gut microbiota and metabolites. J Ethnopharmacol,2024,321:117402.
[13] Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells,2020,9(4):875.
[14] Ye Z, Huang Q, She Y, et al. A meritorious integrated medical regimen for hepatic fibrosis and its complications via thesystematic review and meta-analysis for dahuang zhechong pill-based therapy. Front Med (Lausanne),2022,9:920062.
[15] Cai FF, Wu R, Song YN,et al. Yinchenhaodecoction alleviates liver fibrosis by regulating bile acid metabolism and TGF-β/Smad/ERK signalling pathway. Sci Rep,2018,8(1):15367.
[16] Zhang H, Wang X, Hu P, et al. Serum metabolomic characterization of liver fibrosis in rats and anti-fibrotic effects ofyin-chen-hao-tang. Mole,2016,21(1):126.
[17] Cai FF, Bian YQ, Wu R, et al. Yinchenhao decoction suppressesrat liver fibrosis involved in an apoptosis regulation mechanism based on network pharmacology and transcriptomic analysis. Biomed Pharmacother,114:108863.
[18] Tang DD, Zhang Q, Duan H, et al. Polydatin:a critical promising natural agent for liver protection via antioxidative stress. Oxid Med Cell Longev,2022(2):9218738.
[19] Cheng K, Niu JY, Zheng XT, et al. Aflatoxin-B1-exposure-induced hepatic injury could be alleviated by polydatin through reducing oxidative stress, inhibiting inflammation and improving mitophagy. Toxics,2023,11(4):309.
[20] Zhou Y, Wu R, Cai FF, et al. Xiaoyaosan decoction alleviated rat liver fibrosis via the TGFβ/Smad and Akt/FoxO3 signaling pathways based on network pharmacology analysis. JEP,2021,264:113021.
[21] Zhou Y, Wu R, Cai FF, et al. Development of a novel anti-liver fibrosis formula with luteolin, licochalcone a, aloe-emodin and acacetin by network pharmacology and transcriptomics analysis.Pharm Biol,2021,59(1):1594-1606.
[22] 陶庆,王晓柠,慕永平,等. 四氯化碳诱导大鼠肝纤维化脂质过氧化相关蛋白表达的动态变化及一贯煎的干预效应.中华肝脏病杂志,2012,20(2):116-121.
[23] Xu Y, Xu W, Liu W, et al. Yiguanjian decoction inhibits macrophage M1 polarization and attenuates hepatic fibrosis induced by CCl4/2-AAF. Pharm Biol,2021,59(1):1150-1160.
[24] 范晔,郝坤艳,李平,等. 扶正化瘀组方治疗乙型肝炎肝纤维化或肝硬化疗效的荟萃分析.中华肝脏病杂志,2024,32(12):1141-1152.
[25] 王林,卢玮,高玉华,等. 安络化纤丸对肝纤维化大鼠肝组织基质金属蛋白酶及其抑制物表达的影响.中华肝脏病杂志,2019,27(4):267-273.
[26] Wang F, Gan J, Li R, et al. Naringin fromganshuang granule inhibits inflammatory to relieve liver fibrosis through TGF-β-Smad signaling pathway. PLoS One,19(6):e0304185.
[27] You CR, Lee SW, Jang JW, et al. Update on hepatitis B virus infection. World J Gastroenterol,2014,20(37):13293-305.
[28] 赵鸿,斯崇文,魏来,等. 聚乙二醇化干扰素α-2b与干扰素α-2b治疗e抗原阳性慢性乙型肝炎的疗效和安全性的随机对照多中心研究.中华肝脏病杂志,2006,14(5):323-326.
[29] Gu L, Zhu Y, Lee M, et al. Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. PNAS,2023,120(19): e2300706120.
[30] 曹伟,闫蕾,王玮,等. 辛伐他汀抑制肝星状细胞活化及其对腺苷酸活化蛋白激酶活性的影响.中华肝脏病杂志,2012,20(4):304-309.
[31] Kitsugi K, Noritake H, Matsumoto M, et al. Simvastatin inhibits hepatic stellate cells activation by regulating the ferroptosis signaling pathway. Biochim Biophys Acta Mol Basis Dis,2023,1869(7):166750.
[32] Ibrahim SA, Mohamed MZ, El-Tahawy NF, et al. Antifibrotic effects of bezafibrate and pioglitazone against thioacetamide-induced liver fibrosis in albino rats. Can J Physiol Pharm,2021,99(3):313-320.
[33] 贾晋斌,刘燕,陈尉华,等. 吡格列酮对转化生长因子β诱导的大鼠肝星状细胞的影响.中华肝脏病杂志,2007,15(3):192-195.
[34] Zhang C, Liu XQ, Sun HN, et al. Octreotide attenuates hepatic fibrosis and hepatic stellate cells proliferation and activation by inhibiting Wnt/β-catenin signaling pathway, c-Myc and cyclin D1. Int Immunopharmacol,2018,63:183-190.
[35] Sun Y, Liu B, Xie J, et al. Aspirin attenuates liver fibrosis by suppressing TGF-β1/Smad signaling. Mol Med Rep,2022,25(5):181.
[36] Wang T, Fu X, Jin T, et al. Aspirin targets P4HA2 through inhibiting NF-κB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma.EBioMedicine,2019,45:168-180.
[37] Karimi J,Mohammadalipour A,Sheikh N,et al.Protective effects of combined losartan and nilotinib on carbon tetrachloride (CCl (4))-induced liver fibrosis in rats.Drug Chem Toxicol,2020,43(5):468-478.
[38] Hassan MH,Ghobara MM.Antifibrotic effect of meloxicam in rat liver: role of nuclear factor kappa b,proinflammatory cytokines,and oxidative stress.N-S Arch Pharmacol,2016,389(9):971-983.
[39] 刘梅,郑瑞丹,窦爱霞,等. 多烯磷脂酰胆碱对人肝星状细胞增殖和氧应激及转化生长因子β1表达的影响.中华肝脏病杂志,2007,15(12):945-946.
[40] Wu M, Zhou Y, Qin SL, et al. Fuzheng huayu capsule attenuates hepatic fibrosis by inhibiting activation of hepatic stellate cells. Evid Based Complement Alternat Med,2020(1):3468791.
[41] Zhang T, Yang Y, Wang B,et al. Meta-analysis of influences of biejiajian pill combined with entecavir on serum liver fibrosis markers of compensatory period of hepatitis b cirrhosis: protocol of systematic review and meta-analysis. Medicine (Baltimore),2019,98(51):e18458.
[42] 万贵香,李忠廉,赵亚博,等.恩替卡韦联合扶正解毒散结方治疗乙型肝炎肝硬化患者疗效研究.实用肝脏病杂志,2024,27(2):234-237.

Chinese traditional and western medicine in the treatment of liver fibrosis:current state of the art, controversies, and perspectives

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yao Yu, Ning Bo. Pathogenesis,spontaneous recanalization and anticoagulation therapy in patients with liver cirrhosis and portal vein thrombosis [J]. Journal of Practical Hepatology, 2025, 28(6): 801-804.
[2]	Yang Siqi, Chen Jiawei, Li Shaohan, et al. Improvement of liver steatosis of Coprococcus eutactus in mice with MCD-induced metabolic-associated fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(6): 813-817.
[3]	Hua Qi, Liu Qiong, Chen Qi. Rescue antiviral therapy of tenofovir alafenamide in entecavir-treated chronic hepatitis B patients with low level viremia [J]. Journal of Practical Hepatology, 2025, 28(6): 818-821.
[4]	Jiang Chanjuan, Shao Jingyuan, Xu Lin. Efficacy and safety of albavir/gravir in the treatment of patients with chronic hepatitis C with underlying chronic renal disease [J]. Journal of Practical Hepatology, 2025, 28(6): 822-825.
[5]	Wang Chaojie, Xie Qun, Jiang Hai, et al. Antiviral efficacy of 3D regimen in the treatment of patients with naïve genotype 1b-infected chronic hepatitis C [J]. Journal of Practical Hepatology, 2025, 28(6): 826-829.
[6]	Li Hui, Tao Ya, Xu Xunmei, et al. Efficacy of liraglutide in the treatment of patients with NAFLD and T2DM and its impact on peripheral blood mononuclear cell NLRP3, Caspase-1 and ASC levels [J]. Journal of Practical Hepatology, 2025, 28(6): 830-833.
[7]	Zheng Huihui, Wang Yurong, Xu Ting. Combination of Xuezhikang and atorvastatin in treatment of patients with non-alcoholic fatty liver disease and hyperlipidemia [J]. Journal of Practical Hepatology, 2025, 28(6): 834-837.
[8]	Wang Meiling, Li Jie, Liu Juan, et al. Semaglutide in combination with fenofibrate in the treatment of patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(6): 838-841.
[9]	Gao Hai’na, Liang Pan, Gao Linhui, et al. Combination of exenatide and metformin in treatment of patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: A pilot study [J]. Journal of Practical Hepatology, 2025, 28(6): 842-845.
[10]	Chen Xiaoling, Zhang Panpan, Fu Yufang, et al. Clinical efficacy of semaglutidein combination with Huatan Quyu Tongluo decoction in the treatment of patients with NAFLD and T2DM: A pilot study [J]. Journal of Practical Hepatology, 2025, 28(6): 846-849.
[11]	Tian Weiwei, Sun Jiaqi, Chen Ken, et al. Efficacy of standard immunosuppressive therapy with combination of diammonium glycyrrhizinate in the treatment of patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2025, 28(6): 854-857.
[12]	Huang Xiaoli, Shen Jie. Entecavir antiviral treatment with daily outcutaneous irradiation of infrared ray in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(6): 878-881.
[13]	Chen Shanshan, Si Xiaochuang, Zhu Jiabao, et al. Diagnostic performance of liver shear wave velocity and various noninvasive parameter combination in the assessment of liver cirrhosis in patients with primary biliary cholangitis [J]. Journal of Practical Hepatology, 2025, 28(6): 886-889.
[14]	Yang Lan, Xu Shijie, Bao Huaxin. Serum FGFR1, VEGFA and IRX5 level changes in patients with hepatocellular carcinoma after TACE treatment [J]. Journal of Practical Hepatology, 2025, 28(6): 890-893.
[15]	Li Jianlin, Li Ya, Zheng Qiuran, et al. ¹²⁵I radioactive seed implantation in combination with TACE in the treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2025, 28(6): 894-897.